Article
Author: Lefrere, François ; Gobert, Delphine ; Puyade, Matthieu ; Fain, Olivier ; Audia, Sylvain ; Malphettes, Marion ; Cottu, Adrien ; Godeau, Bertrand ; Cheze, Stéphane ; Marolleau, Jean-Pierre ; Limal, Nicolas ; Martis, Nihal ; Viallard, Jean-François ; Perlat, Antoinette ; Galicier, Lionel ; Moignet-Autrel, Aline ; Bonnotte, Bernard ; Morin, Anne-Sophie ; Noel, Nicolas ; Lega, Jean-Christophe ; Gerfaud-Valentin, Mathieu ; Michel, Marc ; Languille, Laetitia ; Roy-Peaud, Frédérique ; Guillet, Stéphanie ; Comont, Thibault ; Graveleau, Julie ; Rivière, Etienne ; Robbins, Ailsa ; Mahevas, Matthieu ; Moulis, Guillaume ; Lambotte, Olivier ; Neel, Antoine ; Crickx, Etienne ; Terriou, Louis ; Le Gallou, Thomas ; Boutin, Emmanuelle
AbstractIn an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.